Drug Profile


Alternative Names: MK-3814; Privadenant; SCH 420814

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antiparkinsonians; Bridged-ring heterocyclic compounds; Piperazines; Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Drug-induced dyskinesia; Parkinson's disease

Most Recent Events

  • 07 Apr 2017 Merck plans the MK-3814A-062 phase I trial for Solid tumours (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease) in USA, Canada and Israel (NCT03099161)
  • 23 May 2013 Discontinued - Phase-I for Drug-induced dyskinesia in USA (PO)
  • 23 May 2013 Discontinued - Phase-II for Parkinson's disease (mid/late-stage) in Latin America (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top